bluuebunny/crossref_metadata_2025_split huggingface dataset:
Protective effects of Scrophularia striata in Ovalbumin-induced mice asthma model
Authors: Azadmehr Abbas , Hajiaghaee Reza , Zohal Mohammad Ali , Maliji Ghorban 
Published: July 2013

Abstract

Background

Scrophularia striata Boiss. (Scrophulariaceae) is a plant growing in the northeastern part of Iran and being used as a traditional herb for various inflammatory disorders.
This study was designed to investigate the protective effects of the Scrophularia striata extract in Ovalbumin (OVA) induced-asthma mice model.

Methods
OVA-sensitized mice were intrapritonealy treated with two doses (100 and 200 mg/kg) of the extract on days 8 to 14 separately. Broncoalveolar lavage fluids (BALF) was collected 48 h after the final OVA challenge and then the number of eosinophils and other inflammatory cells were assessed by direct microscopic counting. In addition, total immunoglubolin (Ig) E and OVA-specific IgE levels in serum, IL-4 and IL-5 cytokines in BALF were determined by Enzyme-Linked Immunosorbent Assay. Moreover, phytochemical assay by thin layer chromatography (TLC) and the 2, 2 diphenyl-1-picrylhydrazyl (DPPH) were used to evaluate the main compounds and the antioxidant capacity of the plant extract, respectively.

Results
The results showed that the main components; including flavonoids, phenolic compounds and phenyl propanoids were presented in the S. striata extract. In addition, the treatment with extract significantly reduced the number of inflammatory cells and suppressed T-helper 2 (Th2) cytokines including IL-4 and IL-5 in BALF. Also, total IgE and OVA-specific IgE levels in the serum decreased.

Conclusion
Collectively, it is concluded that the extract has the potential to modulate the Th2 cytokines and could be used as immunomodulatory agent in the treatment of allergic asthma.
Does the effectiveness of forest protected areas differ conditionally on their type of governance?
Authors: Macura Biljana , Secco Laura , Pullin Andrew S 
Published: July 2013

AbstractBackgroundIn context of protected areas (PAs), governance can be defined as a set of processes, procedures, resources, institutions and actors that determine how decisions are made and implemented. Current governance modes of forest PAs are multilevel and complex, with a variety of actors, different levels of power sharing, various formal and informal rules and vested interests. However, there is no systematic information on how different local governance modes and day-to-day decision-making processes within forest PAs may cause a change in PA effectiveness in terms of producing desired conservation outcomes. In this review we aim to assess relative effectiveness of forest PAs worldwide with respect to different governance modes and linking them to the multiple outcomes in order to discern the effective governance strategies for biodiversity and forest conservation. We will evaluate effectiveness of forest protected areas by multiple outcome measures: 1) attitudes of local stakeholders towards forest protected area governance, 2) conservation-related behaviour of local stakeholders, 3) ecological parameters such as forest cover, biodiversity level, density, overall forest condition and/or health as well as 4) existence of local spillover effects defined as social, institutional and ecological effects in surrounding social-ecological systems.MethodsTo gather empirical evidence on the effectiveness and outcomes of different governance arrangements of forest protected areas, we will search electronic databases, organizational websites, use web search engines and perform a bibliographic search. Articles will be filtered by title, abstract and full text. To facilitate understanding of predictors and conditions for effective PAs, both qualitative and quantitative data from the relevant studies will be extracted and integrated. Multivariate statistical analyses will be performed to give insights into association between different governance modes, their characteristics and PA effectiveness. Finally, the review will report on data gaps and potential for future empirical research.
Role of biomarkers in the management of antibiotic therapy: an expert panel review: I – currently available biomarkers for clinical use in acute infections
Authors: Dupuy Anne-Marie , Philippart François , Péan Yves , Lasocki Sigismond , Charles Pierre-Emmanuel , Chalumeau Martin , Claessens Yann-Eric , Quenot Jean-Pierre , Guen Christele Gras-Le , Ruiz Stéphanie , Luyt Charles-Edouard , Roche Nicolas , Stahl Jean-Paul , Bedos Jean-Pierre , Pugin Jérôme , Gauzit Rémy , Misset Benoit , Brun-Buisson Christian ,   for the Maurice Rapin Institute Biomarkers Group
Published: July 2013

Abstract
In the context of worldwide increasing antimicrobial resistance, good antimicrobial prescribing in more needed than ever; unfortunately, information available to clinicians often are insufficient to rely on. Biomarkers might provide help for decision-making and improve antibiotic management. The purpose of this expert panel review was to examine currently available literature on the potential role of biomarkers to improve antimicrobial prescribing, by answering three questions: 1) Which are the biomarkers available for this purpose?; 2) What is their potential role in the initiation of antibiotic therapy?; and 3) What is their role in the decision to stop antibiotic therapy? To answer these questions, studies reviewed were limited to recent clinical studies (<15 years), involving a substantial number of patients (>50) and restricted to controlled trials and meta-analyses for answering questions 2 and 3. With regard to the first question concerning routinely available biomarkers, which might be useful for antibiotic management of acute infections, these are currently limited to C-reactive protein (CRP) and procalcitonin (PCT). Other promising biomarkers that may prove useful in the near future but need to undergo more extensive clinical testing include sTREM-1, suPAR, ProADM, and Presepsin. New approaches to biomarkers of infections include point-of-care testing and genomics.
Proteolytic enzymes from Bromelia antiacantha as tools for controlled tissue hydrolysis in entomology
Authors: Macció Laura , Vallés Diego , Cantera Ana Maria 
Published: July 2013

Abstract
A crude extract with high proteolytic activity (78.1 EU/mL), prepared from ripe fruit of Bromelia antiacantha was used to hydrolyze and remove soft tissues from the epigyne of Apopyllus iheringi. This enzymatic extract presented four actives isoforms which have a broad substrate specificity action. Enzyme action on samples was optimized after evaluation under different conditions of pH, enzyme-substrate ratio and time (parameters selected based on previous studies) of treatment (pH 4.0, 6.0 and 8.0 at 42°C with different amount of enzyme). Scanning electron microscopy was used to evaluate conditions resulting in complete digestion of epigyne soft tissues. Optimal conditions for soft tissue removal were 15.6 total enzyme units, pH 6.0 for 18 h at 42°C.
Modulation of monosodium urate crystal-induced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications
Authors: Gagné Valérie , Marois Louis , Levesque Jean-Michel , Galarneau Hugo , Lahoud Mireille H , Caminschi Irina , Naccache Paul H , Tessier Philippe , Fernandes Maria JG 
Published: July 2013

Abstract
Introduction
Monosodium urate crystals (MSU), the etiological agent of gout, are one of the most potent proinflammatory stimuli for neutrophils. The modulation of MSU-induced neutrophil activation by inhibitory receptors remains poorly characterized. The expression of the myeloid inhibitory C-type lectin-like receptor (MICL) in neutrophils is downregulated by several proinflammatory stimuli, suggestive of a role for this receptor in neutrophil function. We thus investigated the potential role of MICL in MSU-induced neutrophil activation.

Methods
The expression of MICL was monitored in human neutrophils by flow cytometry and Western blot analysis after stimulation with MSU. Protein tyrosine phosphorylation was also assessed by Western blot analysis and the production of IL-1 and IL-8 by enzyme-linked immunosorbent assay. Changes in the concentration of cytoplasmic free calcium were monitored with the Fura-2-acetoxymethyl ester calcium indicator. MICL expression was modulated with an anti-MICL antibody in neutrophils and siRNA in the PLB-985 neutrophil-like cell line.

Results
MSU induced the downregulation of MICL expression in neutrophils. A diminution in the expression of MICL induced by antibody cross-linking or siRNA enhanced the MSU-dependent increase in cytoplasmic calcium levels, protein tyrosine phosphorylation and IL-8 but not IL-1 production. Pretreatment of neutrophils with colchicine inhibited the MSU-induced downregulation of MICL expression.

Conclusions
Our findings strongly suggest that MICL acts as an inhibitory receptor in human neutrophils since the downregulation of MICL expression enhances MSU-induced neutrophil activation. Since MSU downregulates the expression of MICL, MICL may play a pathogenic role in gout by enhancing neutrophil effector functions. In support of this notion, colchicine counteracts the MSU-induced loss of MICL expression. Our findings thus also provide further insight into the potential molecular mechanisms behind the anti-inflammatory properties of this drug.
Reducing Treatment Decision Conflict Difficulties in Breast Cancer Surgery: A Randomized Controlled Trial
Authors: Lam Wendy W.T. , Chan Miranda , Or Amy , Kwong Ava , Suen Dacita , Fielding Richard 
Published: July 2013

Purpose Breast cancer (BC) decision aid (DA) randomized studies are limited to DA use in consultations among Western populations and for primary surgery. Their effectiveness beyond consultations, for reconstructive surgery and in other populations, has not been evaluated. We developed a DA administered after consultation for Chinese women deciding on BC surgery and, where relevant, immediate breast reconstruction, which was evaluated in this randomized controlled trial (RCT). Patients and Methods Overall, 276 women considering BC surgery for early-stage BC were randomly assigned to receive a DA (take-home booklet) or the standard information booklet (control condition) after the initial consultation, wherein surgeons disclosed the diagnosis and discussed treatment options with patients. Using block random assignment by week, 138 women were assigned to the DA arm and 138 to the control arm. Participants completed interview-based questionnaires 1 week after consultation and then 1, 4, and 10 months after surgery. Primary outcome measures were decisional conflict, decision-making difficulties, BC knowledge 1 week after consultation, and decision regret 1 month after surgery. Secondary outcome measures were treatment decision, decision regret 4 and 10 months after surgery, and postsurgical anxiety and depression. Results The DA group reported significantly lower decisional conflict scores 1 week after consultation (P = .016) compared with women in the control arm. Women receiving the DA had significantly lower decision regret scores 4 (P = .026) and 10 months (P = .014) after surgery and lower depression scores 10 months after surgery (P = .001). Conclusion This RCT demonstrated DAs may benefit Chinese patients in Hong Kong by reducing decisional conflict and subsequent regret and enhance clinical services for this population.
Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
Authors: Morschhauser Franck Andre , Cartron Guillaume , Thieblemont Catherine , Solal-Céligny Philippe , Haioun Corinne , Bouabdallah Reda , Feugier Pierre , Bouabdallah Krimo , Asikanius Elina , Lei Guiyuan , Wenger Michael , Wassner-Fritsch Elisabeth , Salles Gilles Andre 
Published: July 2013

Purpose Obinutuzumab (GA101), a type II, glycoengineered, humanized anti-CD20 monoclonal antibody, was superior to rituximab in human diffuse large B-cell lymphoma (DLBCL) and mantle-cell lymphoma (MCL) xenograft models. In phase I of our study, obinutuzumab (GA101) exhibited encouraging activity but no clear dose-response relationship, and few patients had aggressive histologies. The efficacy and safety of two doses of obinutuzumab (GA101) were explored in our randomized phase II trial in patients with heavily pretreated DBLCL and MCL. Patients and Methods Patients were randomly assigned to receive eight cycles of obinutuzumab (GA101) either as a flat dose of 400 mg for all infusions (days 1 and 8 of cycle 1; day 1 of cycles 2 to 8) or 1,600 mg on days 1 and 8 of cycle 1 and 800 mg on day 1 of cycles 2 to 8. Results Forty patients were enrolled: 21 patients in the 400/400-mg treatment arm (DLBCL, n = 10; MCL, n = 11) and 19 patients in the 1,600/800-mg arm (DLBCL, n = 15; MCL, n = 4). End-of-treatment response was 28% (32% and 24% in the 1,600/800-mg and 400/400-mg study arms, respectively). Best overall response rates were 37% in the 1,600/800-mg arm and 24% in the 400/400-mg study arm (DLBCL, eight [32%] of 25 patients; MCL, four [27%] of 15 patients). Five (20%) of 25 rituximab-refractory patients exhibited treatment response, including four of 12 in the 1,600/800-mg group. The most common adverse events were infusion-related reactions (IRRs), which were manageable. Three patients had grade 3/4 IRRs. Grade 3/4 neutropenia was seen in only one patient. Conclusion Obinutuzumab (GA101) 1,600/800 mg achieves early steady-state concentration and clinical activity with an acceptable safety profile in relapsed/refractory DLBCL and MCL, supporting further exploration.
Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation Therapy
Authors: Olivotto Ivo A. , Whelan Timothy J. , Parpia Sameer , Kim Do-Hoon , Berrang Tanya , Truong Pauline T. , Kong Iwa , Cochrane Brandy , Nichol Alan , Roy Isabelle , Germain Isabelle , Akra Mohamed , Reed Melanie , Fyles Anthony , Trotter Theresa , Perera Francisco , Beckham Wayne , Levine Mark N. , Julian Jim A. 
Published: July 2013

Purpose To report interim cosmetic and toxicity results of a multicenter randomized trial comparing accelerated partial-breast irradiation (APBI) using three-dimensional conformal external beam radiation therapy (3D-CRT) with whole-breast irradiation (WBI). Patients and Methods Women age > 40 years with invasive or in situ breast cancer ≤ 3 cm were randomly assigned after breast-conserving surgery to 3D-CRT APBI (38.5 Gy in 10 fractions twice daily) or WBI (42.5 Gy in 16 or 50 Gy in 25 daily fractions ± boost irradiation). The primary outcome was ipsilateral breast tumor recurrence (IBTR). Secondary outcomes were cosmesis and toxicity. Adverse cosmesis was defined as a fair or poor global cosmetic score. After a planned interim cosmetic analysis, the data, safety, and monitoring committee recommended release of results. There have been too few IBTR events to trigger an efficacy analysis. Results Between 2006 and 2011, 2,135 women were randomly assigned to 3D-CRT APBI or WBI. Median follow-up was 36 months. Adverse cosmesis at 3 years was increased among those treated with APBI compared with WBI as assessed by trained nurses (29% v 17%; P < .001), by patients (26% v 18%; P = .0022), and by physicians reviewing digital photographs (35% v 17%; P < .001). Grade 3 toxicities were rare in both treatment arms (1.4% v 0%), but grade 1 and 2 toxicities were increased among those who received APBI compared with WBI (P < .001). Conclusion 3D-CRT APBI increased rates of adverse cosmesis and late radiation toxicity compared with standard WBI. Clinicians and patients are cautioned against the use of 3D-CRT APBI outside the context of a controlled trial.
Global gene expression profiling of pancreatic islets in mice during streptozotocin-induced β-cell damage and pancreatic Glp-1 gene therapy
Authors: Tonne Jason M. , Sakuma Toshie , Deeds Michael C. , Munoz-Gomez Miguel , Barry Michael A. , Kudva Yogish C. , Ikeda Yasuhiro 
Published: July 2013

Summary
Streptozotocin (STZ), a glucosamine-nitrosourea compound, has potent genotoxic effects on pancreatic β-cells and is frequently used to induce diabetes in experimental animals. Glucagon-like peptide-1 (GLP-1) has β-cell protective effects and is known to preserve β-cells from STZ treatment. In this study, we analyzed the mechanisms of STZ-induced diabetes and GLP-1-mediated β-cell protection in STZ-treated mice. At 1 week after multiple low-dose STZ administrations, pancreatic β-cells showed impaired insulin expression, while maintaining expression of nuclear Nkx6.1. This was accompanied by significant upregulation of p53-responsive genes in islets, including a mediator of cell cycle arrest, p21 (also known as Waf1 and Cip1). STZ treatment also suppressed expression of a wide range of genes linked with key β-cell functions or diabetes development, such as G6pc2, Slc2a2 (Glut2), Slc30a8, Neurod1, Ucn3, Gad1, Isl1, Foxa2, Vdr, Pdx1, Fkbp1b and Abcc8, suggesting global β-cell defects in STZ-treated islets. The Tmem229B, Prss53 and Ttc28 genes were highly expressed in untreated islets and strongly suppressed by STZ, suggesting their potential roles in β-cell function. When a pancreas-targeted adeno-associated virus (AAV) vector was employed for long-term Glp-1 gene delivery, pancreatic GLP-1 expression protected mice from STZ-induced diabetes through preservation of the β-cell mass. Despite its potent β-cell protective effects, however, pancreatic GLP-1 overexpression showed limited effects on the global gene expression profiles in the islets. Network analysis identified the programmed-cell-death-associated pathways as the most relevant network in Glp-1 gene therapy. Upon pancreatic GLP-1 expression, upregulation of Cxcl13 and Nptx2 was observed in STZ-damaged islets, but not in untreated normal islets. Given the pro-β-cell-survival effects of Cxcl12 (Sdf-1) in inducing GLP-1 production in α-cells, pancreatic GLP-1-mediated Cxcl13 induction might also play a crucial role in maintaining the integrity of β-cells in damaged islets.
Insights into the pathogenic character of a commonNUBPLbranch-site mutation associated with mitochondrial disease and complex I deficiency using a yeast model
Authors: Wydro Mateusz M. , Balk Janneke 
Published: July 2013

SummaryComplex I deficiencies are the most common causes of mitochondrial disorders. They can result from mutations not only in the structural subunits but also in a growing number of known assembly factors. A branch-site mutation in the human gene encoding assembly factor NUBPL has recently been associated with mitochondrial encephalopathy and complex I deficiency in seven independent cases. Moreover, the mutation is present in 1.2% of European haplotypes. To investigate its pathogenicity, we have reconstructed the altered C-terminus that results from the branch-site mutation and frameshift in the homologous Ind1 protein in the respiratory yeast Yarrowia lipolytica. We demonstrate that the altered sequence did not affect IND1 mRNA stability, yet it led to a decrease in Ind1 protein level. The instability of mutant Ind1 resulted in a strong decrease in complex I activity and caused slow growth, resembling the phenotype of the deletion strain of IND1. The presented data confirms the deleterious impact of the altered C-terminus resulting from the branch-site mutation. Furthermore, our approach demonstrates the great potential of Y. lipolytica as a model to investigate complex I deficiencies, especially in cases with genetic complexity.
Phylogenetics, morphological evolution, and classification of Euphorbia subgenus Euphorbia
Authors: Dorsey Brian L. , Haevermans Thomas , Aubriot Xavier , Morawetz Jeffery J. , Riina Ricarda , Steinmann Victor W. , Berry Paul E. 
Published: July 2013

AbstractEuphorbia subg. Euphorbia is the largest and most diverse of four recently recognized subgenera within Euphorbia and is distributed across the tropics and subtropics. Relationships within this group have been difficult to discern due mainly to homoplasious morphological characters and inadequate taxon sampling in previous phylogenetic studies. Here we present a phylogenetic analysis of E. subg. Euphorbia, using one nuclear and two plastid regions, for the most complete sampling of molecular sequence data to date. We assign 661 species to the subgenus and show that it is comprised of four highly supported clades, including a single New World clade and multiple independent lineages on Madagascar. Using this phylogenetic framework we discuss patterns of homoplasy in morphological evolution and general patterns of biogeography. Finally, we present a new sectional classification of E. subg. Euphorbia comprising 21 sections, nine of them newly described here.
Molecular phylogenetics of Chelonopsis (Lamiaceae: Gomphostemmateae) as inferred from nuclear and plastid DNA and morphology
Authors: Xiang Chun-Lei , Zhang Qiang , Scheen Anne-Cathrine , Cantino Philip D. , Funamoto Tsuneo , Peng Hua 
Published: July 2013

AbstractThe recently established tribe Gomphostemmateae (Lamiaceae) consists of Gomphostemma, Bostrychanthera and Chelonopsis, but relationships within and between these genera have not been well studied. Only six of the approximately 46 species of Gomphostemmateae have been included in any previous phylogenetic analysis. In the present study, we used DNA sequences of two nuclear regions (ITS, ETS) and five plastid loci (psbA–trnH, rps16, trnL intron, trnL–trnF spacer, trnS–trnG) to reconstruct the phylogeny of the East Asian genus Chelonopsis for the first time. The molecular results indicate that the tribe Gomphostemmateae is monophyletic; Bostrychanthera is embedded in Chelonopsis; and Chelonopsis comprises two clades, one encompassing the taxa of Chelonopsis subg. Chelonopsis and the genus Bostrychanthera and the other consisting of Chelonopsis subg. Aequidens. This split is supported by several morphological characters. These results, which are further strengthened by morphological and cytological data, indicate that Bostrychanthera should be transferred to Chelonopsis. In addition, our results show that within C. subg. Aequidens, sect. Aequidens and sect. Microphyllum are monophyletic. Furthermore, two major clades are concordant with the Sino–Japanese and Sino–Himalayan distribution patterns.
Global legume diversity assessment: Concepts, key indicators, and strategies
Authors: Yahara Tetsukazu , Javadi Firouzeh , Onoda Yusuke , de Queiroz Luciano Paganucci , Faith Daniel P. , Prado Darién E. , Akasaka Munemitsu , Kadoya Taku , Ishihama Fumiko , Davies Stuart , Slik J.W. Ferry , Yi Tingshuang , Ma Keping , Bin Chen , Darnaedi Dedy , Pennington R. Toby , Tuda Midori , Shimada Masakazu , Ito Motomi , Egan Ashley N. , Buerki Sven , Raes Niels , Kajita Tadashi , Vatanparast Mohammad , Mimura Makiko , Tachida Hidenori , Iwasa Yoh , Smith Gideon F. , Victor Janine E. , Nkonki Tandiwe 
Published: July 2013

AbstractWhile many plant species are considered threatened under anthropogenic pressure, it remains uncertain how rapidly we are losing plant species diversity. To fill this gap, we propose a Global Legume Diversity Assessment (GLDA) as the first step of a global plant diversity assessment. Here we describe the concept of GLDA and its feasibility by reviewing relevant approaches and data availability. We conclude that Fabaceae is a good proxy for overall angiosperm diversity in many habitats and that much relevant data for GLDA are available. As indicators of states, we propose comparison of species richness with phylogenetic and functional diversity to obtain an integrated picture of diversity. As indicators of trends, species loss rate and extinction risks should be assessed. Specimen records and plot data provide key resources for assessing legume diversity at a global scale, and distribution modeling based on these records provide key methods for assessing states and trends of legume diversity. GLDA has started in Asia, and we call for a truly global legume diversity assessment by wider geographic collaborations among various scientists.